Val30Met-transthyrethin amyloid polyneuropathy and cardiomyopathy (review of literature and case report)
- Authors: Gudkova A.Y.1,2, Amelin A.V1, Krutikov A.N1,2, Poliakova A.A1,2, Safyanova N.V1, Shavlovskiy M.M2,3, Khmelnitskaya K.A1, Korzhevsky D.E3, Semernin E.N1
-
Affiliations:
- I.P.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation
- Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation
- Institute of Experimental Medicine
- Issue: Vol 19, No 12 (2017)
- Pages: 109-116
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/94957
- DOI: https://doi.org/10.26442/2075-1753_19.12.109-116
- ID: 94957
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
A. Ya Gudkova
I.P.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation; Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation
Email: alexagood-1954@mail.ru
д-р мед. наук, проф. каф. факультетской терапии, зав. лаб. кардиомиопатий Института сердечно-сосудистых заболеваний, вед. науч. сотр. Института молекулярной биологии и генетики 197022, Russian Federation, Saint Petersburg, ul. L'va Tolstogo, d. 6/8
A. V Amelin
I.P.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation
Email: avamelin@mail.ru
д-р мед. наук, проф. каф. неврологии с клиникой 197022, Russian Federation, Saint Petersburg, ul. L'va Tolstogo, d. 6/8
A. N Krutikov
I.P.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation; Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation
Email: ankrutikov@yandex.ru
вед. науч. сотр. НИО инфильтративных заболеваний сердца Института молекулярной биологии и генетики 197022, Russian Federation, Saint Petersburg, ul. L'va Tolstogo, d. 6/8
A. A Poliakova
I.P.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation; Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation
Email: lica.polyakova@mail.ru
ст. науч. сотр. НИО инфильтративных заболеваний сердца Института молекулярной биологии и генетики, мл. науч. сотр. лаб. кардиомиопатий Института сердечно-сосудистых заболеваний 197022, Russian Federation, Saint Petersburg, ul. L'va Tolstogo, d. 6/8
N. V Safyanova
I.P.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation
Email: nsafyanova@yandex.ru
врач-кардиолог Городской поликлиники №31 197022, Russian Federation, Saint Petersburg, ul. L'va Tolstogo, d. 6/8
M. M Shavlovskiy
Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation; Institute of Experimental Medicine
Email: mmsch@rambler.ru
д-р мед. наук, проф. каф. медицинской генетики вед. науч. сотр. лаб. кардиомиопатий Института сердечно-сосудистых заболеваний 197376, Russian Federation, Saint Petersburg, ul. Akademika Pavlova, d. 12
K. A Khmelnitskaya
I.P.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federationканд. мед. наук, ст. науч. сотр. лаб. кардиомиопатий Института сердечно-сосудистых заболеваний 197022, Russian Federation, Saint Petersburg, ul. L'va Tolstogo, d. 6/8
D. E Korzhevsky
Institute of Experimental Medicineд-р мед. наук, проф. РАН, зав. лаб. функциональной морфологии центральной и периферической нервной системы 197376, Russian Federation, Saint Petersburg, ul. Akademika Pavlova, d. 12
E. N Semernin
I.P.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation
Email: e.semernin@yandex.ru
канд. мед. наук, рук. отд. НИО инфильтративных заболеваний сердца Института молекулярной биологии и генетики 197022, Russian Federation, Saint Petersburg, ul. L'va Tolstogo, d. 6/8
References
- Sekijima Y, Kelly J.W, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des 2008; 14 (30): 3219-30.
- Sekijima Y, Uchiyama S, Tojo K. et al. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol 2011; 42: 1785-91. doi: 10.1016/j.humpath.2011.03.004
- Sipe J.D, Benson MD, Buxbaum J.N. et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid 2016; 23 (4): 209-13. doi: 10.1080/13506129.2016.1257986
- Connors L.H, Sam F, Skinner M. et al. Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin A Prospective, Observational Cohort Study. Circulation. 2016; 133: 282-90. doi: 10.1161/CIRCULATIONAHA. 115.018852
- Andrade C, Canijo M, Klein D. et al. The genetic aspects of the familial amyloidotic polyneuropathy: Portuguese type of amyloidosis. Hum Genet 1969; 7: 163-75.
- Sebastião M.P, Lamzin V, Saraiva M.J. et al. Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution. J Mol Biol 2001; 306: 733-44. doi: 10.1006/jmbi.2000.4415
- Plante-Bordeneuve V. Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy. J Neurol 2014; 261 (6): 1227-33. doi: 10.1007/s00415-014-7373-0
- Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011; 10 (12): 1086-97. doi: 10.1016/S1474-4422(11)70246-0
- Maurer M.S, Hanna M, Grogan M. et al. THAOS Investigators. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 2016; 68 (2): 161 72. doi: 10.1016/j.jacc. 2016.03.596
- Misu K, Hattori N, Nagamatsu M. et al. Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Brain 1999; 122: 1951-62.
- Conceição I, de Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve 2007; 35 (1): 116-8. doi: 10.1002/mus.20644
- Sobue G, Koike H, Misu K. et al. Clinicopathologic and genetic features of early- and late-onset FAP type I (FAP ATTR Val30Met) in Japan. Amyloid 2003; 10 (Suppl. 1): 32-8.
- Conceição I, González-Duarte A, Obici L. et al. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 2016; 21 (1): 5-9. doi: 10.1111/jns.12153
- Dubrey S.W, Hawkins P.N, Falk R.H. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart 2011; 97 (1): 75-84. doi: 10.1136/hrt.2009.190405
- Elliott P.M, Anastasakis A, Borger M.A. et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J 2014; 35: 2733-79. doi: 10.1093/eurheartj/ehu284
- Hoyer C, Angermann C.E, Knop S. et al. Cardiac amyloidosis. Med Klin (Munich) 2008; 103 (3): 153-60. doi: 10.1007/s00063-008-1022-2
- Hassan W, Al-Sergani H, Mourad W. et al. Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management. Tex Heart Inst J 2005; 32 (2): 178-84.
- Hongo M, Yamamoto H, Kohda T. et al. Comparison of electrocardiographic findings in patients with AL (primary) amyloid polyneuropathy and angina pain and their relation to histopathologic findings. Am J Cardiol 2000; 85: 849-53.
- Papachan A, Sliwa K, Gildenhuys A. et al. Cardiac amyloidosis presenting as pseudo-hypertrophic cardiomyopathy. Cardivascular J S Africa 2004; 15 (3): 136-8.
- Ando Y, Coelho T, Berk J.L. et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 2013; 20 (8): 31. doi: 10.1186/1750-1172-8-31
- Hou X, Aguilar M.I, Small D.H. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J 2007; 274: 1637-50. doi: 10.1111/j.1742-4658.2007.05712.x
- Coelho T, Maurer M.S, Suhr O.B. et al. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 2013; 29 (1): 63-76. doi: 10.1185/03007995.2012.754348
- Adams D, Lozeron P, Lacroix C. et al. Amyloid neuropathies. Curr Opin Neurol 2012; 25: 564-72. doi: 10.1097/WCO.0b013e328357bdf6
- Adams D, Lozeron P, Theaudin M. et al. Regional difference and similarity of familial amyloidosis with polyneuropathy in France. Amyloid 2012; 19 (Suppl. 1): 61-4. doi: 10.3109/13506129.2012.685665
- Goto T, Yamashita T, Ueda M. et al. Iatrogenic amyloid neuropathy in a Japanese patient after sequential liver transplantation. Am J Transplant 2006; 6 (10): 2512-5. doi: 10.1111/j.1600-6143.2006.01484.x
- Yamashita T, Ando Y, Okamoto S. et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 2012; 78 (9): 637-43. doi: 10.1212/WNL.0b013e318248df18
- Herlenius G, Wilczek H.E, Larsson M. et al. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004, 77: 64-71. doi: 10.1097/01.TP.00000092307.98347.C.B
- Bulawa C.E, Connelly S, Devit M. et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 2012; 109: 9629-34. doi: 10.1073/pnas.1121005109
- Maurer M.S, Grogan DR, Judge D.P. et al. Tafamidis in transthyretin amyloid cardiomyopathy: Effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail 2015; 8 (3): 519-26. doi: 10.1161/CIRCHEARTFAILURE.113.000890
- Berk J.L, Dyck PJ, Obici L. et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid 2011; 18 (Suppl. 1): 191-2. doi: 10.3109/13506129.2011.574354073
- Sekijima Y, Dendle MA, Kelly J.W. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 2006; 13: 236-49. doi: 10.1080/13506120600960882
- Tojo K, Sekijima Y, Kelly J.W. et al. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res 2006; 56: 441-9. doi: 10.1016/j.neures.2006.08.014.
- Johnson S.M, Connelly S, Fearns C. et al. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 2012; 421 (2-3): 185-203. DOI: 10.1016/ j.jmb.2011.12.060
- Adams D, Cauquil C, Labeyrie C. et al. TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies. Expert Opin Pharmacother 2016; 17 (6): 791-802. doi: 10.1517/14656566.2016.1145664